Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 8/20 | 0.49 |
| ▸ | CTSK | P43235 | 7/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | CCKAR | P32238 | 2/20 | 0.42 |
| ▸ | CCKBR | P32239 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507966 | 0.86 | PIM1 (0.45) | — | |
| SCHEMBL6515100 | 0.80 | CTSS (0.41) | AKT1CTSSCTSKCTSBCTSL | |
| SCHEMBL6518001 | 0.78 | PLK1 (0.48) | AKT1CTSSCTSKCTSBCTSL | |
| SCHEMBL6519358 | 0.78 | AKT1 (0.46) | AKT1CTSSCTSKCTSBCTSL | |
| SCHEMBL6513772 | 0.77 | AKT1 (0.46) | AKT1CTSSCTSKCTSBCTSL | |
| SCHEMBL6514615 | 0.74 | PIK3R1 (0.41) | — | |
| SCHEMBL2440946 | 0.74 | CTSS (0.79) | AKT1CTSSCTSKCTSBCTSL | |
| SCHEMBL21010315 | 0.74 | CTSS (0.79) | AKT1CTSSCTSKCTSBCTSL | |
| SCHEMBL22915477 | 0.73 | AKT1 (1.00) | AKT1CTSSCTSKCTSBCTSL | |
| SCHEMBL2446582 | 0.72 | CTSS (0.76) | AKT1CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | AKT1 475/4885CTSS 983/4885CTSK 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.